Zacks: Analysts Expect Sangamo Therapeutics Inc (SGMO) Will Post Earnings of -$0.10 Per Share

Wall Street brokerages expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to announce earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is $0.07 and the lowest is ($0.24). Sangamo Therapeutics posted earnings per share of ($0.15) during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is expected to issue its next earnings report on Thursday, November 8th.

On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.29). For the next financial year, analysts anticipate that the firm will report earnings of ($0.78) per share, with EPS estimates ranging from ($1.06) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s quarterly revenue was up 159.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share.

SGMO has been the topic of a number of research reports. BidaskClub lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Tuesday, May 1st. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Bank of America began coverage on shares of Sangamo Therapeutics in a research note on Wednesday, June 20th. They set a “buy” rating and a $24.00 price target for the company. Finally, Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a research note on Monday, July 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $22.29.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $15.38, for a total value of $76,900.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $188,405. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 30,000 shares of company stock valued at $458,700. 1.20% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. NumerixS Investment Technologies Inc bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $125,000. Riverhead Capital Management LLC increased its stake in Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,667 shares in the last quarter. Tyers Asset Management LLC increased its stake in Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 7,232 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in Sangamo Therapeutics by 301.3% in the second quarter. Meadow Creek Investment Management LLC now owns 16,856 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 12,656 shares in the last quarter. Finally, Tiverton Asset Management LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $242,000. 57.49% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics traded up $0.35, reaching $15.65, on Friday, MarketBeat.com reports. The stock had a trading volume of 2,113,880 shares, compared to its average volume of 1,967,697. Sangamo Therapeutics has a 1-year low of $9.50 and a 1-year high of $27.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.78 and a current ratio of 7.24.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply